查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1699344

连网药物输送设备市场机会、成长动力、产业趋势分析及 2025-2034 年预测

Connected Drug Delivery Devices Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034
出版日期: | 出版商: Global Market Insights Inc. | 英文 130 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2024 年全球连网药物输送设备市场价值为 4.912 亿美元，预计 2025 年至 2034 年期间将以 31.8% 的强劲复合年增长率扩张。这些设备整合了蓝牙、Wi-Fi 和物联网 (IoT) 等现代技术，以改善药物管理和管理。它们包括智慧吸入器、胰岛素笔、穿戴式註射器和智慧药丸分配器，旨在监测药物使用、增强依从性并实现患者和医疗保健提供者之间的即时沟通。气喘、糖尿病和心血管疾病等慢性病的发病率上升，推动了对这些先进药物传递系统的需求。药物依从性差是医疗保健领域的一个长期存在的问题，导致医疗成本增加和病患治疗效果不佳。连网药物输送设备可确保适当的药物摄取、简化疾病管理和减少医院就诊次数，从而帮助解决这些问题。

连网药物传输设备市场 - IMG1

根据设备类型，市场分为连接感测器和整合设备。 2024 年，整合设备占据了最大的收入份额，为 60.9%。这些设备配备了提醒、追踪功能和即时数据共享功能，显着提高了患者对治疗计划的依从性。远端监控药物摄取的能力加强了其在医疗保健环境中的采用。慢性病的日益普及进一步扩大了对综合药物输送解决方案的需求。

市场范围
起始年份 2024
预测年份 2025-2034
起始值 4.912亿美元
预测值 72.5亿美元
复合年增长率 31.8%

根据技术，市场分为蓝牙、近场通讯和 Wi-Fi。 2024 年，蓝牙领域的收入份额最高，为 47.7%。低功耗、经济实惠以及与行动健康应用的无缝整合推动了支援蓝牙的药物输送设备的广泛应用。这些设备促进了患者和医疗保健提供者之间的即时资料交换，支援远端监控和数位健康平台。随着慢性病发病率的上升，支援蓝牙的智慧吸入器、胰岛素笔和自动注射器的需求正在增加。此外，製药和医疗科技公司对蓝牙为基础的生物感测器和穿戴式註射器的投资不断增加，正在加强市场扩张。

根据应用，市场分为过敏反应、呼吸系统、心血管、糖尿病、荷尔蒙替代和其他用途。 2024 年，呼吸系统疾病领域创造了 2.21 亿美元的最高收入。气喘、慢性阻塞性肺病 (COPD) 和其他呼吸系统疾病的负担日益加重，增加了对连网药物输送解决方案的需求。这些设备不仅提高了治疗依从性，还支援远端患者监控，加强了远距医疗服务的扩展。

根据最终用途，市场也细分为医院、诊所、家庭护理机构等。家庭护理领域在 2024 年的收入达到 1.985 亿美元，居家护理领域占据领先地位。由于人口老化和慢性病管理需求的不断增长，人们对家庭医疗保健的偏好日益增长，这刺激了对连网药物输送系统的需求。这些设备支援自我管理和远端监控，使患者能够更有效地管理自己的病情。

美国连网药物输送设备市场规模预计将从 2023 年的 1.56 亿美元大幅成长至 2034 年的 27 亿美元。远距医疗服务的日益普及，尤其是在 COVID-19 疫情之后，加速了用于远距医疗监控的连网设备的部署。

目录

第一章：方法论与范围

第二章：执行摘要

第三章：行业洞察

  • 产业生态系统分析
  • 产业衝击力
    • 成长动力
      • 提高患者对遵守处方治疗的认识
      • 快速发展的医疗保健IT基础设施
      • 机器学习和人工智慧的采用率飙升
      • 整合 AR/VR 技术的远距医疗平台应用日益增多
    • 产业陷阱与挑战
      • 有关患者资料的安全问题
      • 设备价格高
  • 成长潜力分析
  • 监管格局
  • 技术格局
  • 未来市场趋势
  • 差距分析
  • 波特的分析
  • PESTEL分析

第四章：竞争格局

  • 介绍
  • 公司市占率分析
  • 公司矩阵分析
  • 主要市场参与者的竞争分析
  • 竞争定位矩阵
  • 策略仪表板

第五章：市场估计与预测：按设备类型，2021 年至 2034 年

  • 主要趋势
  • 连接的传感器
    • 连接的吸入感测器
    • 连接注射感测器
  • 整合设备
    • 集成吸入装置
    • 整合注射装置

第六章：市场估计与预测：按技术，2021 年至 2034 年

  • 主要趋势
  • 蓝牙
  • 近场通讯
  • 无线上网

第七章：市场估计与预测：按应用，2021 年至 2034 年

  • 主要趋势
  • 过敏反应
  • 呼吸系统
  • 心血管
  • 糖尿病
  • 荷尔蒙替代
  • 其他应用

第八章：市场估计与预测：依最终用途，2021 年至 2034 年

  • 主要趋势
  • 医院
  • 诊所
  • 居家照护环境
  • 其他最终用途

第九章：市场估计与预测：按地区，2021 年至 2034 年

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 波兰
    • 瑞士
    • 荷兰
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 泰国
    • 印尼
    • 越南
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 秘鲁
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋
    • 以色列

第十章：公司简介

  • Adherium
  • Aptar Pharma
  • AstraZeneca
  • Becton, Dickinson, and Company
  • Bigfoot Biomedical
  • Cohero Health
  • Eli Lilly and Company
  • Insulet Corporation
  • Novartis
  • Novo Nordisk
  • Phillips Medisize
  • Propeller Health
  • Teva Pharmaceuticals
  • West Pharmaceutical Services
  • Ypsomed
简介目录
Product Code: 4422

The Global Connected Drug Delivery Devices Market was valued at USD 491.2 million in 2024 and is anticipated to expand at a robust CAGR of 31.8% from 2025 to 2034. These devices integrate modern technology, such as Bluetooth, Wi-Fi, and the Internet of Things (IoT), to improve medication management and administration. They include smart inhalers, insulin pens, wearable injectors, and intelligent pill dispensers, all designed to monitor medication usage, enhance adherence, and enable real-time communication between patients and healthcare providers. The rising incidence of chronic conditions, including asthma, diabetes, and cardiovascular diseases, is fueling demand for these advanced drug delivery systems. Poor medication adherence is a persistent issue in healthcare, leading to higher costs and suboptimal patient outcomes. Connected drug delivery devices help address these concerns by ensuring proper medication intake, streamlining disease management, and reducing hospital visits.

Connected Drug Delivery Devices Market - IMG1

The market is segmented based on device type into connected sensors and integrated devices. Integrated devices accounted for the largest revenue share of 60.9% in 2024. These devices, equipped with reminders, tracking features, and real-time data-sharing capabilities, significantly improve patient compliance with treatment plans. The ability to monitor medication intake remotely has strengthened their adoption across healthcare settings. The increasing prevalence of chronic illnesses has further amplified the demand for integrated drug delivery solutions.

Market Scope
Start Year2024
Forecast Year2025-2034
Start Value$491.2 Million
Forecast Value$ 7.25 Billion
CAGR31.8%

Based on technology, the market is divided into Bluetooth, near field communication, and Wi-Fi. The Bluetooth segment held the highest revenue share of 47.7% in 2024. Low power consumption, affordability, and seamless integration with mobile health applications have driven the widespread adoption of Bluetooth-enabled drug delivery devices. These devices facilitate real-time data exchange between patients and healthcare providers, supporting remote monitoring and digital health platforms. With the rising incidence of chronic diseases, Bluetooth-enabled smart inhalers, insulin pens, and autoinjectors are witnessing increased demand. Additionally, growing investments by pharmaceutical and MedTech companies in Bluetooth-based biosensors and wearable injectors are strengthening market expansion.

By application, the market is categorized into anaphylaxis, respiratory, cardiovascular, diabetes, hormone replacement, and other uses. The respiratory segment generated the highest revenue of USD 221 million in 2024. The increasing burden of asthma, chronic obstructive pulmonary disease (COPD), and other respiratory disorders has amplified the need for connected drug delivery solutions. These devices not only improve treatment adherence but also support remote patient monitoring, strengthening the expansion of telehealth services.

The market is also segmented by end use into hospitals, clinics, home care settings, and others. The home care segment led with USD 198.5 million in revenue in 2024. The growing preference for home-based healthcare, driven by an aging population and the rising need for chronic disease management, has fueled demand for connected drug delivery systems. These devices enable self-administration and remote monitoring, allowing patients to manage their conditions more efficiently.

The U.S. connected drug delivery devices market is projected to grow significantly from USD 156 million in 2023 to USD 2.7 billion by 2034. The increasing adoption of telehealth services, particularly after the COVID-19 pandemic, has accelerated the deployment of connected devices for remote healthcare monitoring.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates and calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 3600 synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising patient awareness about adherence to prescribed therapies
      • 3.2.1.2 Rapidly moving healthcare IT infrastructure
      • 3.2.1.3 Soaring adoption of machine learning, and artificial intelligence
      • 3.2.1.4 Rising implementation of telehealth platform integrated with AR/VR technologies
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 Security concerns regarding patient data
      • 3.2.2.2 High price of devices
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Technological landscape
  • 3.6 Future market trends
  • 3.7 Gap analysis
  • 3.8 Porter's analysis
  • 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Device Type, 2021 – 2034 ($ Mn)

  • 5.1 Key trends
  • 5.2 Connected sensors
    • 5.2.1 Connected inhalation sensors
    • 5.2.2 Connected injectable sensors
  • 5.3 Integrated devices
    • 5.3.1 Integrated inhalation devices
    • 5.3.2 Integrated injectable devices

Chapter 6 Market Estimates and Forecast, By Technology, 2021 – 2034 ($ Mn)

  • 6.1 Key trends
  • 6.2 Bluetooth
  • 6.3 Near field communication
  • 6.4 Wi-Fi

Chapter 7 Market Estimates and Forecast, By Application, 2021 – 2034 ($ Mn)

  • 7.1 Key trends
  • 7.2 Anaphylaxis
  • 7.3 Respiratory
  • 7.4 Cardiovascular
  • 7.5 Diabetes
  • 7.6 Hormone replacement
  • 7.7 Other applications

Chapter 8 Market Estimates and Forecast, By End Use, 2021 – 2034 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospitals
  • 8.3 Clinics
  • 8.4 Home care settings
  • 8.5 Other end use

Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Poland
    • 9.3.7 Switzerland
    • 9.3.8 Netherlands
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
    • 9.4.6 Thailand
    • 9.4.7 Indonesia
    • 9.4.8 Vietnam
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
    • 9.5.4 Columbia
    • 9.5.5 Peru
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE
    • 9.6.4 Israel

Chapter 10 Company Profiles

  • 10.1 Adherium
  • 10.2 Aptar Pharma
  • 10.3 AstraZeneca
  • 10.4 Becton, Dickinson, and Company
  • 10.5 Bigfoot Biomedical
  • 10.6 Cohero Health
  • 10.7 Eli Lilly and Company
  • 10.8 Insulet Corporation
  • 10.9 Novartis
  • 10.10 Novo Nordisk
  • 10.11 Phillips Medisize
  • 10.12 Propeller Health
  • 10.13 Teva Pharmaceuticals
  • 10.14 West Pharmaceutical Services
  • 10.15 Ypsomed